Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

SNSS 7.24 +0.24 (3.43%)
price chart
Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short ...
Sunesis Pharmaceuticals is nearing a binary event with the top-line data readout of its Phase 3 Valor trial that is expected any day now.
Related articles »  
Biotech Stocks Under Review -- Keryx Biopharma, Sangamo BioSciences ...
Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. KERX, +1.70% Sangamo BioSciences Inc. SGMO, +1.14% Regeneron Pharmaceuticals Inc. REGN, +0.16% Sunesis Pharmaceuticals Inc. SNSS, +2.29% and Idera ...
Related articles »  
Wedbush Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Neutral
Wedbush downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Outperform to Neutral with a price target of $10 (unchanged).
Live News Buzz: IGI Laboratories, Inc.(NYSEMKT:IG), Sunesis Pharmaceuticals ...  Market News Call
Sunesis Pharmaceuticals major shareholder Sells $2125599 in Stock (SNSS)  WKRB News
Related articles »  
Sunesis Pharmaceuticals Inc. (SNSS) Drops 5.47% on August 28
Sunesis Pharmaceuticals Inc. (SNSS) was one of the Russell 2000's biggest losers for August 28 as the stock slid 5.47% to $7.78, a loss of $0.45 per share.
Related articles »  
Stocks to Watch : JA Solar Holdings (NASDAQ:JASO), Sunesis Pharmaceuticals ...
Sunesis Pharmaceuticals Inc (NASDAQ:SNSS) CEO Daniel N. Swisher, Jr. sold 5,000 shares of Sunesis Pharmaceuticals stock in a transaction that occurred on Wednesday, August 27th.
Related articles »  
Stocks to Keep Your Eyes On: Sunesis Pharmaceuticals, Inc. (SNSS), Aspen ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) plummeted 3.73 percent to $7.49 in the last trading session after Wedbush cut its ratings for the biopharmaceutical company from �Outperform� to �Neutral� in a research report sent to investors on August 29.
Morning Watch List : Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Move, Inc ...
On 29 Aug Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an �outperform� rating to a �neutral� rating in a research note on Friday.
Sunesis Pharmaceuticals Hits New 1-Year High at $7.71 (SNSS)
Sunesis Pharmaceuticals logo Sunesis Pharmaceuticals (NASDAQ:SNSS)'s share price hit a new 52-week high during trading on Monday , AnalystRatings.
Notable Movers � Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Synta ...  Techsonian (press release)
Investors Purchase Large Volume of Put Options on Sunesis Pharmaceuticals ...  Mideast Time
Related articles »  
Biotech Sector's Great Run: Amicus Therapeutics, Inc. (FOLD), Sunesis ...
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) scored more than 3-year high after an analyst said success is �more likely than not� for the company's development drug for leukemia.
Investors Buy Large Volume of Sunesis Pharmaceuticals Put Options (SNSS)
Sunesis Pharmaceuticals logo Sunesis Pharmaceuticals (NASDAQ:SNSS) was the recipient of unusually large options trading on Tuesday.
Sunesis Pharmaceuticals Sees Unusually High Options Volume (SNSS)  Ticker Report
Stocks in the Spotlight: Echelon Corporation (ELON), Sunesis Pharmaceuticals ...  Techsonian (press release)
Related articles »